Q1 2025 Earnings Forecast for Medexus Pharmaceuticals Inc. (TSE:MDP) Issued By Stifel Canada

Medexus Pharmaceuticals Inc. (TSE:MDPFree Report) – Investment analysts at Stifel Canada issued their Q1 2025 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Wednesday, June 26th. Stifel Canada analyst J. Keywood expects that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.25 per share. Stifel Canada also issued estimates for Medexus Pharmaceuticals’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.04) EPS.

Separately, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, June 26th.

View Our Latest Stock Report on Medexus Pharmaceuticals

Medexus Pharmaceuticals Stock Performance

Medexus Pharmaceuticals stock opened at C$1.82 on Monday. The firm has a market cap of C$44.52 million, a PE ratio of 4.55 and a beta of 1.82. Medexus Pharmaceuticals has a twelve month low of C$1.44 and a twelve month high of C$3.53. The firm’s 50 day moving average price is C$1.67 and its two-hundred day moving average price is C$1.88.

About Medexus Pharmaceuticals

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

See Also

Earnings History and Estimates for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.